Why Teva's (TEVA) Stock Is Higher Today

NEW YORK (TheStreet) -- Shares of Teva Pharmaceuticals (TEVA) are higher by 6.29% to 52.56, as the U.S. Supreme Court today decided that it will hear an appeal filed by the Israel-based pharmaceutical and drug company that develops, produces and markets generic drugs in all treatment categories.

The company is in a patent fight over its best selling multiple sclerosis drug Copaxone, a move that could see generic manufacturers steer away from introducing cheaper versions onto the market as soon as this May.

Copaxone is a branded drug of Teva's that makes up some 20% of its sales and about 50% of profits.

Must Read: Warren Buffett's 10 Favorite Stocks

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

TheStreet Ratings team rates TEVA PHARMACEUTICALS as a Buy with a ratings score of B. TheStreet Ratings Team has this to say about their recommendation:

"We rate TEVA PHARMACEUTICALS (TEVA) a BUY. This is driven by some important positives, which we believe should have a greater impact than any weaknesses, and should give investors a better performance opportunity than most stocks we cover. The company's strengths can be seen in multiple areas, such as its revenue growth, increase in net income, expanding profit margins, largely solid financial position with reasonable debt levels by most measures and solid stock price performance. We feel these strengths outweigh the fact that the company has had somewhat disappointing return on equity."

Highlights from the analysis by TheStreet Ratings Team goes as follows:

If you liked this article you might like

Dollar Tree CEO Calls It Quits, Joining List of Executive Departures This Year

S&P 500 and Dow Score Records With Wall Street Upbeat Ahead of Fed

S&P 500 and Dow on Track for Records With Markets in Good Mood Ahead of Fed

S&P 500 and Dow Aim for New Records With Broad-Based Gains Ahead of Fed

Dow and S&P 500 Reach New Intraday Highs With Markets in Good Mood Ahead of Fed